RITUXIREL contains rituximab, a chimeric IgG1 monoclonal antibody directed against the CD20 antigen found on certain B lymphocytes. By binding to CD20, rituximab promotes depletion of CD20-positive B cells through several immune-mediated mechanisms. This can reduce abnormal B-cell populations in selected cancers and autoimmune diseases.
The medication may be recommended for patients with:
Rituximab has an extensive clinical evidence base. Clinical studies have demonstrated its efficacy in various B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. Rituximab has also been extensively studied in rheumatoid arthritis and ANCA-associated vasculitis. A major clinical trial evaluated rituximab versus cyclophosphamide for remission induction in granulomatosis with polyangiitis and microscopic polyangiitis.
A phase III comparative clinical study has also evaluated the efficacy and safety of RituxiRel versus reference rituximab in patients with non-Hodgkin lymphoma.
The medication is used to treat selected diseases involving abnormal CD20-positive B lymphocytes. Major therapeutic areas for rituximab include certain forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Depending on the approved indication of the specific product and the clinical situation, rituximab is also used for rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Rituximab binds to CD20 on B lymphocytes and activates immune mechanisms that reduce the number of these cells. This targeted action affects abnormal B-cell populations and may help control malignant or autoimmune disease processes.
The medication is administered only by intravenous infusion by a healthcare professional. Before administration, it is diluted according to the official prescribing information. The dose, infusion rate, number of infusions, and treatment duration depend on the disease, treatment regimen, and individual patient factors. Self-administration is not permitted; patients must be medically monitored during infusion because of the risk of infusion-related reactions.
Side Effects
